A Single-blind RCT to Investigate the Effect of a Novel Herbal Patch for the Treatment of PF
Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 17, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new herbal patch to see if it can help treat plantar fasciitis, a common condition that causes pain in the heel and bottom of the foot. Plantar fasciitis often results from repetitive stress on a thick band of tissue that supports the foot arch, leading to discomfort and difficulty walking. The study aims to determine if this herbal patch can effectively relieve pain and improve the quality of life for those suffering from this condition.
To be eligible for the trial, participants need to be between 18 and 65 years old and have been experiencing heel pain for more than six weeks, with a pain level of 5 or higher on a scale from 0 to 10. The study is open to both men and women and will exclude individuals with certain health conditions or recent surgeries that could affect the results. Participants can expect to receive the herbal patch and will be monitored throughout the study to assess its effectiveness. This trial is an exciting opportunity for those looking for new treatment options for their foot pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female with age 18-65
- • Unilateral or bilateral
- • Heel pain for more than 6 weeks' duration
- • VAS score ≥ 5
- • Signed informed consent.
- Exclusion Criteria:
- • Known chronic disease or receiving long-term medications affecting bone metabolism including BPs
- • Contraindication to alendronate therapy such as poor dental fitness
- • ACL injury less than 6 weeks
- • Injury on duty cases
- • Patients who have undergone arthroscopy or open surgery in the index knee in the last 12 months
- • Other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury)
- • Chondral lesion with concomitant intervention
- • Presence of X-ray features of osteoarthritis including decrease in joint space, presence of osteophytes and subchondral cysts
- • Neurological deficit
- • Pregnant or breastfeeding
- • Inability to give informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sha Tin, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials